Avadel Pharmaceuticals announced that the FDA has approved LUMRYZ, an extended-release formulation of sodium oxybate for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy, and has granted Orphan Drug Exclusivity for seven years.